Andagao, Cheryl V.
HRN: 06-28-78 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/28/2023
CO-AMOXICLAV 625MG (TAB)
04/28/2023
05/05/2023
ORAL
625mg/tab
TID
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes